Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.53 |
| ▸ | TSHR | P16473 | 1/20 | 0.53 |
| ▸ | NOS3 | P29474 | 1/20 | 0.49 |
| ▸ | NOS1 | P29475 | 1/20 | 0.49 |
| ▸ | NOS2 | P35228 | 1/20 | 0.49 |
| ▸ | PDK1 | Q15118 | 12/20 | 0.48 |
| ▸ | LTB4R2 | Q9NPC1 | 1/20 | 0.47 |
| ▸ | PDK2 | Q15119 | 2/20 | 0.44 |
| ▸ | PDK4 | Q16654 | 2/20 | 0.44 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3060075 | 0.95 | GAA (0.53) | GAATSHRNOS3NOS1NOS2 | |
| SCHEMBL3065409 | 0.91 | GAA (0.63) | GAATSHRPDK1LTB4R2PDK2 | |
| SCHEMBL3053783 | 0.91 | GAA (0.51) | GAATSHRNOS3NOS1NOS2 | |
| SCHEMBL3059962 | 0.89 | GAA (0.54) | GAATSHRPDK1LTB4R2 | |
| SCHEMBL3050032 | 0.89 | NOS3 (0.55) | GAATSHRNOS3NOS1NOS2 | |
| SCHEMBL3043584 | 0.88 | GAA (0.51) | GAATSHRNOS3NOS1NOS2 | |
| SCHEMBL3053488 | 0.88 | MAPK14 (0.54) | GAATSHRNOS3NOS1NOS2 | |
| SCHEMBL3052473 | 0.87 | NOS3 (0.61) | GAATSHRNOS3NOS1NOS2 | |
| SCHEMBL3056522 | 0.87 | ATF1 (0.57) | GAATSHRNOS3NOS1NOS2 | |
| SCHEMBL3062368 | 0.86 | GAA (0.64) | GAATSHRPDK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100261758-A1 | HETEROCYCLIC AMIDES FOR USE AS PHARMACEUTICALS | NOVARTIS AG (CH) | 2010-10-14 | — | — | US | disclosed |
| CN-101405268-A | Amide derivatives and their use for the treatment of protein-related diseases | NOVARTIS AG (CH) | 2009-04-08 | — | — | CN | disclosed |
| EP-2001851-A2 | AMIDE DERIVATIVES AND THEIR APPLICATION FOR THE TREAMENT OF G PROTEIN RELATED DISEASES | Novartis AG (CH) | 2008-12-17 | — | — | EP | disclosed |
| WO-2007110237-A2 | AMIDE DERIVATIVES AND THEIR APPLICATION FOR THE TREATMENT OF G PROTEIN RELATED DISEASES | NOVARTIS AG (CH) | 2007-10-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100261758-A1 | HETEROCYCLIC AMIDES FOR USE AS PHARMACEUTICALS | HRH4, CNR1, CNR2 | GAA 1212/4885TSHR 384/4885NOS3 3019/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.